The treatment of deep venous thrombosis, including the newer agents.
Rectenwald
John E
JE
Wakefield
Thomas W
TW
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000401:mortality; D013921:Thrombocytopenia / Q000139:chemically induced; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D014859:Warfarin; D000077425:Fondaparinux